Joint Formulary & PAD

Abaloparatide - Osteoporosis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Subcutaneous injection (sc)
Associated Icons :
Restrictions / Comments :

See PAD for treatment pathway

Documents :
 

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Abaloparatide
Indication :
Osteoporosis
Group Name :
Keywords :
postmenopausal osteoporosis
Brand Names Include :
Eladynos
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Other Indications

Below are listed other indications that Abaloparatide is used to treat.

  • No records returned.

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves abaloparatide for the treatment of osteoporosis as recommended by NICE TA991.

 

Abaloparatide for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians).

 

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.